Academic Progress-BIOTECH PHARMACEUTICAL CO., LTD_EGF Vaccine_ Nimotuzumab

BIOTECH

Home
About Us
About Us

BPL is a high-tech China-Cuba joint venture among first group engaged in the development, production and sales of monoclonal antibodies in China.
S&T
S&T

International-standard humanized monoclonal antibody preparation processes and large-scale, continuous mammalian cell culture technology.
- Research Areas
- Technology Platforms
Research and Development
Research and Development

China has developed nivolumab, a humanized monoclonal antibody drug (trade name: TaiXinSheng), for the treatment of malignant tumors.
Blog
Blog

Integrating industry-related media coverage as well as the company’s various activities and updates.
- Company News
- Media Reports
Join Us
Join Us

Boasting a postdoctoral research workstation and diverse career opportunities, we sincerely invite talented individuals from all fields to join Baite.
- Post-Doctoral Center
Contact Us
Contact Us

ThaiXinLife Consultation Hotline: +86 4006592330
Company Main Line: +86-10-51571020
- Contact Us

Image Name

Marketed Products

Academic Progress

The groundbreaking NOTABLE study makes a major impact, paving the way for a new era in pancreatic cancer diagnosis and treatment.

The groundbreaking NOTABLE study makes a major impact, paving the way for a new era in pancreatic cancer diagnosis and treatment.

The groundbreaking NOTABLE study makes a major impact, paving the way for a new era in pancreatic cancer diagnosis and treatment.

Professor Qin Shukui and Professor Li Jin lead the release of data on targeted therapy for "king of cancers," pancreatic cancer; studies on bile duct cancer and gastric/gastroesophageal junction cancer also unveiled simultaneously at ASCO 2022.

Professor Qin Shukui and Professor Li Jin lead the release of data on targeted therapy for "king of cancers," pancreatic cancer; studies on bile duct cancer and gastric/gastroesophageal junction cancer also unveiled simultaneously at ASCO 2022.

Professor Qin Shukui and Professor Li Jin lead the release of data on targeted therapy for "king of cancers," pancreatic cancer; studies on bile duct cancer and gastric/gastroesophageal junction cancer also unveiled simultaneously at ASCO 2022.

China's voice resonates across the globe! Live coverage of the keynote presentations by Professors Qin Shukai and Li Jin at the NOTABLE Study Conference—ASCO Live from the Frontline

China's voice resonates across the globe! Live coverage of the keynote presentations by Professors Qin Shukai and Li Jin at the NOTABLE Study Conference—ASCO Live from the Frontline

China's voice resonates across the globe! Live coverage of the keynote presentations by Professors Qin Shukai and Li Jin at the NOTABLE Study Conference—ASCO Live from the Frontline

[Case Share] Issue 159: A Case Report on Nivolumab Treatment for Esophageal Cancer

[Case Share] Issue 159: A Case Report on Nivolumab Treatment for Esophageal Cancer

[Case Share] Issue 159: A Case Report on Nivolumab Treatment for Esophageal Cancer

Nivolumab has achieved a major breakthrough in the treatment of esophageal cancer; interim analysis from the Phase III study was selected for poster discussion at the 2022 ASCO meeting.

Nivolumab has achieved a major breakthrough in the treatment of esophageal cancer; interim analysis from the Phase III study was selected for poster discussion at the 2022 ASCO meeting.

Nivolumab has achieved a major breakthrough in the treatment of esophageal cancer; interim analysis from the Phase III study was selected for poster discussion at the 2022 ASCO meeting.

ASCO 2022 Highlighted Oral Presentation: Long-term Survival Results Revealed for Nivolumab in Locally Advanced Nasopharyngeal Cancer—Significant Therapeutic Efficacy

ASCO 2022 Highlighted Oral Presentation: Long-term Survival Results Revealed for Nivolumab in Locally Advanced Nasopharyngeal Cancer—Significant Therapeutic Efficacy

ASCO 2022 Highlighted Oral Presentation: Long-term Survival Results Revealed for Nivolumab in Locally Advanced Nasopharyngeal Cancer—Significant Therapeutic Efficacy

< 1...44 45 46...88 >

Biotech pharmaceutical co., Ltd

Tel: +86-400-659-2330

Exchange Tel: +86-10-51571020

Email: cooperation@biotechplc.com

BD Dept: bd@biotechplc.com

Image Name

Address：NO.2 Rongjing East Street, Beijing Economic and Technological Development Area, Beijing 100176

Biotech pharmaceutical co., Ltd

互联网药品信息编号：(京)非经营性2016-0046

Powered by：CEglobal

Business License

中企跨境-全域组件 1.92 制作前进入CSS配置样式

导航下拉添加类名.active

在线客服添加返回顶部

右侧在线客服样式 1,2,3 1

图片alt标题设置： BIOTECH PHARMACEUTICAL CO., LTD

表单验证提示文本： Content cannot be empty!

循环体没有内容时： Sorry, no matching items were found.

CSS / JS 文件放置地